Anticipated shortage

Aimovig 70 mg/mL injection

erenumab · 70 mg/mL injection

Aimovig

Reported
12 March 2025
Expected resolution
31 October 2025
TGA reference
TGA-MSI-2025-039
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd

Reason for shortage

Novartis/Amgen global supply renegotiation impacting Australian market allocation for anti-CGRP migraine preventatives.

What to do

  1. 1.
    Ensure you have adequate stockCollect your current prescription promptly to build a small buffer before the anticipated shortage begins.
  2. 2.
    Speak with your prescriber proactivelyDiscuss alternative options now, before the shortage occurs, so a plan is in place.
  3. 3.
    Monitor TGA updatesAnticipated shortages may be resolved before they become active. Check the TGA MSI database regularly.

Suggested alternatives

Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.

Official resources

MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.